Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients

被引:76
|
作者
Fueger, BJ
Weber, WA
Quon, A
Crawford, TL
Allen-Auerbach, MS
Halpern, BS
Ratib, O
Phelps, ME
Czernin, J [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Ahmanson Biol Imaging Ctr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA
基金
奥地利科学基金会;
关键词
breast cancer; LSO; integrated PET/CT; restaging;
D O I
10.1007/s11307-005-0013-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: This study was conducted to compare the clinical stage derived from 2-deoxy-2[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) to that of integrated PET/ computed tomography (CT) in restaged breast cancer patients. Procedures: Fifty-eight female patients (age range 29-80 years, mean age +/- SD, 53.3 +/- 11.7 years) underwent PET/CT restaging for breast cancer. Two experienced nuclear medicine physicians interpreted PET images. A radiologist was added for reading PET/CT studies. A patient-based analysis was performed. Histopathological findings, correlative imaging studies, changes in number, size, and hypermetabolic activity of suspicious lesions and/or patient outcome served as standard of reference for determining the diagnostic accuracy of both modalities. Results: PET staged 79.3% (46/58) of the patients correctly, overstaged seven (12.1%), and understaged five patients (8.6%). Integrated PET/CT staged 89.7% (52/58) of the patients correctly, overstaged four (6.9%), and understaged two patients (3.4%). The staging accuracy of PET/CT was not significantly better than that of PET alone (p = 0.059). Lesions exhibiting mild hypermetabolic activity, benign inflammatory lesions, and physiological variants largely explained incorrect PET findings. Conclusion: Integrated PET/CT only marginally improves the restaging accuracy over PET alone (p = 0.059) in breast cancer patients.
引用
收藏
页码:369 / 376
页数:8
相关论文
共 50 条
  • [1] Performance of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients
    Barbara J. Fueger
    Wolfgang A. Weber
    Andrew Quon
    Tyler L. Crawford
    M. S. Allen-Auerbach
    B. S. Halpern
    Osman Ratib
    Michael E. Phelps
    Johannes Czernin
    [J]. Molecular Imaging and Biology, 2005, 7 : 369 - 376
  • [2] 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography/Computed Tomography in the Management of Melanoma
    A. Iagaru
    A. Quon
    D. Johnson
    S. S. Gambhir
    I. R. McDougall
    [J]. Molecular Imaging and Biology, 2007, 9
  • [3] 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma
    Iagaru, A.
    Quon, A.
    Johnson, D.
    Gambhir, S. S.
    McDougall, I. R.
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2007, 9 (01) : 50 - 57
  • [4] 2-Deoxy-2-[F-18]Fluoro-d-Glucose–Positron Emission Tomography/Computed Tomography Imaging Evaluation of Esophageal Cancer
    Hossein Jadvar
    Robert W. Henderson
    Peter S. Conti
    [J]. Molecular Imaging and Biology, 2006, 8 : 193 - 200
  • [5] 2-deoxy-2-(F-18)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology
    Freebody, John
    Wegner, Eva A.
    Rossleigh, Monica A.
    [J]. WORLD JOURNAL OF RADIOLOGY, 2014, 6 (10): : 741 - 755
  • [6] The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)
    Alexander, Mohab
    Brasic, James Robert
    [J]. CLINICAL NUCLEAR MEDICINE, 2006, 31 (09) : 566 - 567
  • [7] Clinical Value of Combined Positron Emission Tomography/Computed Tomography Imaging in the Interpretation of 2-Deoxy-2-[F-18]fluoro-d-glucose–Positron Emission Tomography Studies in Cancer Patients
    Henry W. D. Yeung
    Heiko Schöder
    Alex Smith
    Mithat Gonen
    Steven M. Larson
    [J]. Molecular Imaging and Biology, 2005, 7 : 229 - 235
  • [8] Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer
    Renee M Moadel
    Andrew V Nguyen
    Elaine Y Lin
    Ping Lu
    Joseph Mani
    M Donald Blaufox
    Jeffrey W Pollard
    Ekaterina Dadachova
    [J]. Breast Cancer Research, 5
  • [9] Positron emission tomography agent 2-deoxy-2-[18F] fluoro-D-glucose has a therapeutic potential in breast cancer
    Moadel, RM
    Nguyen, AV
    Lin, EY
    Lu, P
    Mani, J
    Blaufox, MD
    Pollard, JW
    Dadachova, E
    [J]. BREAST CANCER RESEARCH, 2003, 5 (06) : R199 - R205
  • [10] The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site
    Seve, Pascal
    Billotey, Claire
    Broussolle, Christiane
    Dumontet, Charles
    Mackey, John R.
    [J]. CANCER, 2007, 109 (02) : 292 - 299